Roehler Douglas R, Guy Gery P, Jones Christopher M
National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Atlanta 30341, GA, United States.
National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Atlanta 30341, GA, United States.
Drug Alcohol Depend. 2020 Aug 1;213:108083. doi: 10.1016/j.drugalcdep.2020.108083. Epub 2020 May 25.
Expansion of buprenorphine for opioid use disorder treatment is a core component of the opioid overdose epidemic response. The Comprehensive Addiction and Recovery Act (CARA) of 2016 authorized nurse practitioners (NPs) and physician assistants (PAs) to obtain a DATA-waiver to prescribe buprenorphine. The objectives of this study are to examine national- and county-level buprenorphine prescription dispensing, patterns by patient demographics and clinician specialty, and county-level characteristics associated with buprenorphine dispensing.
Retrospective analysis of buprenorphine prescriptions dispensed from approximately 92% of all retail prescriptions in the US (2017-2018). Analyses include rates of buprenorphine prescriptions dispensed, by patient demographics and prescriber specialty, changes in buprenorphine prescriptions dispensed at the national- and county-level, and county-level characteristics associated with buprenorphine dispensing.
Buprenorphine prescriptions dispensed increased by 9.1% nationally, from 40.7-44.4 per 1000 residents. From 2017 to 2018, NPs (351.9%) and PAs (257.3%) had the largest percent increases in dispensed buprenorphine prescriptions, accounting for 79.6% of the total increase. In 2018, county-level characteristics associated with high buprenorphine dispensing included. among others: greater potential buprenorphine treatment capacity, higher drug overdose death rates, and higher rates of Medicaid enrollment. Rural counties were associated with low buprenorphine dispensing.
Buprenorphine dispensing rates increased in the US from 2017 to 2018, suggesting the addition of NPs and PAs by CARA has contributed to an increase in dispensed buprenorphine prescriptions.
扩大丁丙诺啡用于阿片类药物使用障碍治疗是应对阿片类药物过量流行的核心组成部分。2016年的《综合成瘾与康复法案》(CARA)授权执业护士(NPs)和医师助理(PAs)获得数据豁免以开具丁丙诺啡处方。本研究的目的是检查全国和县级丁丙诺啡处方配药情况、按患者人口统计学特征和临床医生专业划分的模式,以及与丁丙诺啡配药相关的县级特征。
对美国约92%的零售处方(2017 - 2018年)中配出的丁丙诺啡处方进行回顾性分析。分析内容包括按患者人口统计学特征和开处方者专业划分的丁丙诺啡处方配药率、全国和县级丁丙诺啡处方配药的变化,以及与丁丙诺啡配药相关的县级特征。
全国丁丙诺啡处方配药量增加了9.1%,从每1000居民40.7张增加到44.4张。从2017年到2018年,执业护士(351.9%)和医师助理(257.3%)配出的丁丙诺啡处方增加百分比最大,占总增加量的79.6%。2018年,与丁丙诺啡高配药相关的县级特征包括:丁丙诺啡潜在治疗能力更强、药物过量死亡率更高以及医疗补助登记率更高。农村县与丁丙诺啡低配药相关。
2017年至2018年美国丁丙诺啡配药率上升,表明《综合成瘾与康复法案》增加执业护士和医师助理有助于丁丙诺啡处方配药量的增加。